Literature DB >> 9274468

Effect of curing Helicobacter pylori infection on intragastric acidity during treatment with ranitidine in patients with duodenal ulcer.

J Labenz1, B Tillenburg, U Peitz, E Verdú, M Stolte, G Börsch, A L Blum.   

Abstract

BACKGROUND: In patients with duodenal ulcer cure of Helicobacter pylori infection resulted in a pronounced decrease in intragastric pH during treatment with omeprazole. AIM: To test the hypothesis that treatment of H pylori adversely affects the pH response to ranitidine. PATIENTS: Eighteen patients with duodenal ulcer who were infected with H pylori were studied.
METHODS: Twenty four hour pH recordings were performed during treatment with ranitidine (300 mg) at night before and four to six weeks after cure of H pylori infection. Presence of H pylori was assessed by a rapid urease test, culture, histology, and a 13C urea breath test. Also, the fasting gastrin concentrations were measured before and after treatment for H pylori infection.
RESULTS: Cure of H pylori infection resulted in a considerable improvement in both antral and corpus gastritis and a decrease in fasting gastrin concentrations. As a result of the cure the night time intragastric pH during treatment with ranitidine decreased (median pH 6.8 v 5.4; p = 0.007), whereas the acidity during the daytime was not affected.
CONCLUSIONS: In patients with duodenal ulcer the intragastric pH during treatment with ranitidine depends on H pylori. However, the loss of effectiveness in altering pH seems to be less pronounced than previously found with omeprazole.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9274468      PMCID: PMC1027224          DOI: 10.1136/gut.41.1.33

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  13 in total

1.  Elimination of Helicobacter pylori under treatment with omeprazole.

Authors:  M Stolte; B Bethke
Journal:  Z Gastroenterol       Date:  1990-06       Impact factor: 2.000

2.  Intragastric pH during treatment with omeprazole: role of Helicobacter pylori and H. pylori-associated gastritis.

Authors:  E F Verdú; D Armstrong; J P Idström; J Labenz; M Stolte; G Börsch; A L Blum
Journal:  Scand J Gastroenterol       Date:  1996-12       Impact factor: 2.423

3.  Helicobacter pylori infection: physiopathologic implication of N alpha-methyl histamine.

Authors:  A Courillon-Mallet; J M Launay; A M Roucayrol; J Callebert; J P Emond; F Tabuteau; D Cattan
Journal:  Gastroenterology       Date:  1995-04       Impact factor: 22.682

Review 4.  Potent inhibition of gastric acid secretion and ulcer formation by centrally and peripherally administered interleukin-1.

Authors:  Y Taché; E Saperas
Journal:  Ann N Y Acad Sci       Date:  1992       Impact factor: 5.691

5.  Relationships between the degree of Helicobacter pylori colonisation and the degree and activity of gastritis, surface epithelial degeneration and mucus secretion.

Authors:  M Stolte; O Stadelmann; B Bethke; G Burkard
Journal:  Z Gastroenterol       Date:  1995-02       Impact factor: 2.000

6.  Severity of Helicobacter-induced gastric injury correlates with gastric juice ammonia.

Authors:  A T Triebling; M A Korsten; J W Dlugosz; F Paronetto; C S Lieber
Journal:  Dig Dis Sci       Date:  1991-08       Impact factor: 3.199

7.  Heightened inflammatory response and cytokine expression in vivo to cagA+ Helicobacter pylori strains.

Authors:  R M Peek; G G Miller; K T Tham; G I Perez-Perez; X Zhao; J C Atherton; M J Blaser
Journal:  Lab Invest       Date:  1995-12       Impact factor: 5.662

8.  Effect of curing Helicobacter pylori infection on intragastric pH during treatment with omeprazole.

Authors:  E F Verdú; D Armstrong; J P Idström; J Labenz; M Stolte; G Dorta; G Börsch; A L Blum
Journal:  Gut       Date:  1995-12       Impact factor: 23.059

9.  Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer.

Authors:  J Labenz; B Tillenburg; U Peitz; J P Idström; E F Verdú; M Stolte; G Börsch; A L Blum
Journal:  Gastroenterology       Date:  1996-03       Impact factor: 22.682

10.  Nitric oxide mediates the inhibition by interleukin-1 beta of pentagastrin-stimulated rat gastric acid secretion.

Authors:  J V Esplugues; M D Barrachina; S Calatayud; J M Pique; B J Whittle
Journal:  Br J Pharmacol       Date:  1993-01       Impact factor: 8.739

View more
  7 in total

1.  Inhibitory potency of twice-a-day omeprazole on gastric acidity is enhanced by eradication of H. pylori in duodenal ulcer patients.

Authors:  A B R Thomson; M Keelan; R Lastiwka; S Appelman-Eszczuk; L Zuk; L Drozdowski; A Prentice; P Sinclair
Journal:  Dig Dis Sci       Date:  2003-10       Impact factor: 3.199

Review 2.  What is potent acid inhibition, and how can it be achieved?

Authors:  Xavier Calvet; Fernando Gomollón
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 3.  Helicobacter pylori in gastro-oesophageal reflux disease: causal agent, independent or protective factor?

Authors:  J Labenz; P Malfertheiner
Journal:  Gut       Date:  1997-09       Impact factor: 23.059

4.  Influence of sex and Helicobacter pylori on development and healing of gastroduodenal lesions in non-steroidal anti-inflammatory drug users.

Authors:  C J Hawkey; I Wilson; J Naesdal; G Långström; A J Swannell; N D Yeomans
Journal:  Gut       Date:  2002-09       Impact factor: 23.059

Review 5.  Assessment of non-steroidal anti-inflammatory drug (NSAID) damage in the human gastrointestinal tract.

Authors:  Martin W James; Christopher J Hawkey
Journal:  Br J Clin Pharmacol       Date:  2003-08       Impact factor: 4.335

Review 6.  Helicobacter pylori, proton pump inhibitors and gastroesophageal reflux disease.

Authors:  E J Kuipers; E C Klinkenberg-Knol; S G Meuwissen
Journal:  Yale J Biol Med       Date:  1999 Mar-Jun

7.  Helicobacter pylori and gastroesophageal reflux disease.

Authors:  Michele Grande; Federica Cadeddu; Massimo Villa; Grazia Maria Attinà; Marco Gallinella Muzi; Casimiro Nigro; Francesco Rulli; Attilio M Farinon
Journal:  World J Surg Oncol       Date:  2008-07-05       Impact factor: 2.754

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.